Prices delayed by at least 15 minutes | Print
Cizzle Biotechnology Holdings PLC (CIZ)
ORD 0.01POpen
1.875p
Previous close
1.875p
Trade high
1.94p
Volume
6,503,134
Year high
4.00p
Year low
1.68p
Dividend yield
-
Market capitalisation
£6.73 mn
P/E ratio
1.86
ISIN
GB00BNG2VN02
This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stableplasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.
News
Recent trades
Date | Time | Price | Quantity | Value (£) |
---|---|---|---|---|
28/03/2024 | 04:11:12 | 1.8 | 500,000 | 9,000.00 |
28/03/2024 | 03:51:46 | 1.7725 | 18,850 | 334.12 |
28/03/2024 | 03:00:42 | 1.8 | 250,000 | 4,500.00 |
28/03/2024 | 02:59:38 | 1.799 | 56,032 | 1,008.02 |
28/03/2024 | 02:56:16 | 1.8 | 1 | 0.02 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.